LONG-TERM EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS REFRACTORY TO BIOLOGIC THERAPIES: 2-YEAR RESULTS FROM THE PHASE 3 SELECT-PSA 2 STUDY

被引：2
|
作者：
Mease, P. J. [1 ,2 ]
Setty, A. [3 ]
Papp, K. [4 ]
Van den Bosch, F. [5 ]
Tsuji, S. [6 ]
Keiserman, M. [7 ]
Bu, X. [3 ]
Chen, L. [3 ]
Mccaskill, R. [3 ]
Mcdearmon-Blondell, E. [3 ]
Wung, P. [3 ]
Tillett, W. [8 ]
机构：
[1] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Rheumatol, Seattle, WA 98195 USA
[3] AbbVie Inc, Immunol, N Chicago, IL USA
[4] Papp Clin Res & Prob Med Res, Dermatol, Waterloo, ON, Canada
[5] Univ Ghent, VIB Ctr Inflammat Res, Internal Med & Pediat, Ghent, Belgium
[6] Natl Hosp Org, Osaka Minami Med Ctr, Orthopaed Rheumatol, Osaka, Japan
[7] Pontifical Catholic Univ, Sch Med, Rheumatol, Porto Alegre, RS, Brazil
[8] Royal Natl Hosp Rheumat Dis, Rheumatol, Bath, Avon, England
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1897
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS1041
引用
收藏
页码：836 / 837
页数：2
相关论文
共 50 条
  • [21] Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Gossec, Laure
    Mcinnes, Iain B.
    Ritchlin, Christopher T.
    Landewe, Robert B. M.
    Asahina, Akihiko
    Ink, Barbara
    Heinrichs, Andrea
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Coates, Laura C.
    RHEUMATOLOGY AND THERAPY, 2024, 11 (05) : 1363 - 1382
  • [22] Efficacy of Upadacitinib in Patients with Psoriatic Arthritis and Prior Exposure to Anti-TNF Therapy in the SELECT-PsA 2 Trial Through 2 Years
    Mease, Philip J.
    Assad, Rodrigo Luppino
    Tsuji, Shigeyoshi
    Richette, Pascal
    Setty, Arathi
    McDearmon-Blondell, Erin
    Gao, Tianming
    Ciecinski, Sandra
    Van den Bosch, Filip
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4258 - 4261
  • [23] Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2 trials
    Cantini, Fabrizio
    Marchesoni, Antonio
    Novelli, Lucia
    Gualberti, Giuliana
    Marando, Francesca
    McDearmon-Blondell, Erin L.
    Gao, Tianming
    McGonagle, Dennis
    Salvarani, Carlo
    RHEUMATOLOGY, 2024, 63 (11) : 3146 - 3154
  • [24] LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS AT 3 YEARS FROM THE SELECT-COMPARE STUDY
    Fleischmann, R.
    Mysler, E.
    Bessette, L.
    Peterfy, C.
    Durez, P.
    Tanaka, Y.
    Swierkot, J.
    Khan, N.
    Bu, X.
    Li, Y.
    Song, I. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 251 - 252
  • [25] Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 3 Years from the SELECT-COMPARE Study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 1708 - 1710
  • [26] Long-term efficacy and safety of secukinumab in patients with psoriatic arthritis: 5-year (end-of-study) results from the phase 3 FUTURE 2 study
    Mclnnes, Lain B.
    Mease, Philip J.
    Kivitz, Alan J.
    Nash, Peter
    Rahman, Proton
    Rech, Jurgen
    Conaghan, Philip G.
    Kirkham, Bruce
    Navarra, Sandra
    Belsare, Ashwini D.
    Delicha, Eumoprhia M.
    Pricop, Luminita
    LANCET RHEUMATOLOGY, 2020, 2 (04): : E227 - E235
  • [27] Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study
    Fleischmann, Roy
    Mysler, Eduardo
    Bessette, Louis
    Peterfy, Charles G.
    Durez, Patrick
    Tanaka, Yoshiya
    Swierkot, Jerzy
    Khan, Nasser
    Bu, Xianwei
    Li, Yihan
    Song, In-Ho
    RMD OPEN, 2022, 8 (01):
  • [28] BIMEKIZUMAB EFFICACY AND SAFETY IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
    Thaci, Diamant
    Gottlieb, Alice B.
    Asahina, Akihiko
    Lebwohl, Mark
    McInnes, Iain B.
    Warren, Richard
    Boehncke, Wolf-Henning
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Merola, Joseph F.
    ACTA DERMATO-VENEREOLOGICA, 2024, 104
  • [29] Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis refractory to biologic therapy: 2-year clinical and radiographic results from the open-label extension of the SELECT-AXIS 2 study
    Baraliakos, Xenofon
    van der Heijde, Desiree
    Sieper, Joachim
    Inman, Robert Davies
    Kameda, Hideto
    Maksymowych, Walter Peter
    Lagunes-Galindo, Ivan
    Bu, Xianwei
    Wung, Peter
    Kato, Koji
    Shmagel, Anna
    Deodhar, Atul
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [30] Disease Control with Upadacitinib in Patients with Psoriatic Arthritis: A Post Hoc Analysis of the Randomized, Placebo-Controlled SELECT-PsA 1 and 2 Phase 3 Trials
    Mease, Philip
    Kavanaugh, Arthur
    Gladman, Dafna
    FitzGerald, Oliver
    Soriano, Enrique R.
    Nash, Peter
    Feng, Dai
    Lertratanakul, Apinya
    Douglas, Kevin
    Lippe, Ralph
    Gossec, Laure
    RHEUMATOLOGY AND THERAPY, 2022, 9 (04) : 1181 - 1191
12345